CAMBRIDGE, Mass., Dec. 4, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present on its innovative nanoliposomal platform for patients with metastatic breast cancer at the 2015 San Antonio Breast Cancer Symposium, December 8 – 12, 2015 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
The presentations include a trials-in-progress abstract for the MM-302 HERMIONE Phase 2 clinical trial and a trials-in-progress abstract for the Phase 1 clinical trial investigating potential predictive response markers for ONIVYDE™ (irinotecan liposome injection), also known as MM-398 or "nal-IRI." MM-302 is a HER2 targeted liposomal encapsulation of doxorubicin.
- HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1) (Abstract OT3-01-01) Ongoing Trials Poster Session 3, Ongoing Trials – HER2 Presentation: Friday, December 11, 2015 (5:00 PM CT) Exhibit Hall A-B
- A phase 1 study in patients with metastatic breast cancer to evaluate the feasibility of magnetic resonance imaging with ferrumoxytol as a potential biomarker for response to treatment with nanoliposomal irinotecan (nal-IRI, MM-398) (Abstract OT3-02-14) Ongoing Trials Poster Session 3, Ongoing Trials – Chemotherapy Presentation: Friday, December 11, 2015 (5:00 PM CT) Exhibit Hall A-B
Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE™ (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contacts: Media Contact Marianne McMorrow 774-776-1478 email@example.com
Investor Contact: Geoffrey Grande, CFA 617-441-7602 firstname.lastname@example.org
SOURCE Merrimack Pharmaceuticals, Inc.